Genotypic Drug Resistance and Long-Term Mortality in Patients with Triple-Class Antiretroviral Drug Failure

Objective To examine the prevalence of drug-resistance-associated mutations in HIV patients with triple-drug class virological failure (TCF) and their association with long-term mortality. Design Population-based study from the Danish HIV Cohort Study (DHCS). Methods We included all patients in the DHCS who experienced TCF between January 1995 and November 2004, and we performed genotypic resistance tests for International AIDS Society (IAS)-USA primary mutations on virus from plasma samples taken around the date of TCF. We computed time to all-cause death from date of TCF. The relative risk of death according to the number of mutations and individual mutations was estimated by Cox regression analysis and adjusted for potential confounders. Results Resistance tests were done for 133 of the 179 patients who experienced TCF. The median number of resistance mutations was eight (interquartile range 2–10), and 81 (61%) patients had mutations conferring resistance towards all three major drug classes. In a regression model adjusted for CD4+ T-cell count, HIV RNA, year of TCF, age, gender and previous inferior antiretroviral therapy, harbouring ≥9 versus ≤8 mutations was associated with increased mortality (mortality rate ratio [MRR] 2.3 [95% confidence interval (CI) 1.1–4.8]), as were the individual mutations T215Y (MRR 3.4 [95% CI 1.6–7.0]), G190A/S (MRR 3.2 [95% CI 1.6–6.6]) and V82F/A/T/S (MRR 2.5 [95% CI 1.2–5.3]). Conclusions In HIV patients with TCF, the total number of genotypic resistance mutations and specific single mutations predicted mortality.

[1]  C. Nielsen,et al.  Prevalence of Drug Resistance Mutations and Non-B Subtypes in Newly Diagnosed HIV-1 Patients in Denmark , 2003, Scandinavian journal of infectious diseases.

[2]  V. Calvez,et al.  Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure , 2004, Journal of medical virology.

[3]  A. Levy,et al.  Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. , 2004, The Journal of infectious diseases.

[4]  A. Mocroft,et al.  Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. , 2004, The Journal of infectious diseases.

[5]  Victor DeGruttola,et al.  Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns , 2004, Antiviral therapy.

[6]  Amalio Telenti,et al.  Update of the drug resistance mutations in HIV-1: Fall 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[7]  D. Kuritzkes,et al.  Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[8]  H. Sørensen,et al.  Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals , 2005, AIDS.

[9]  Julio S. G. Montaner,et al.  Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.

[10]  G. Lucas Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. , 2005, The Journal of antimicrobial chemotherapy.

[11]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[12]  D. Edwards,et al.  HIV-1 Drug Resistance Evolution Among Patients on Potent Combination Antiretroviral Therapy With Detectable Viremia , 2005, Journal of acquired immune deficiency syndromes.

[13]  P. Harrigan,et al.  Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.

[14]  V. Calvez,et al.  Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients , 2004, Antimicrobial Agents and Chemotherapy.

[15]  M. Wainberg,et al.  Effects of drug resistance on viral load in patients failing antiretroviral therapy , 2006, Journal of medical virology.

[16]  Richard D Moore,et al.  Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing , 2004, AIDS.

[17]  S. Jensen-Fangel,et al.  Demographics of HIV-1 infection in Denmark: Results from the Danish HIV Cohort Study , 2005, Scandinavian journal of infectious diseases.

[18]  A. Zolopa,et al.  High levels of adherence do not prevent accumulation of HIV drug resistance mutations , 2003, AIDS.

[19]  P. Narciso,et al.  Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients , 2005, AIDS.

[20]  H. Sørensen,et al.  Declining Prevalence of HIV-Infected Individuals at Risk of Transmitting Drug-Resistant HIV in Denmark during 1997–2004 , 2005, Antiviral therapy.

[21]  Bruno Ledergerber,et al.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.

[22]  Maurizio Zazzi,et al.  Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. , 2006, The Journal of infectious diseases.

[23]  B. Clotet,et al.  Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy , 2005, Antiviral therapy.

[24]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[25]  D. Richman,et al.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. , 2000, The Journal of infectious diseases.

[26]  A. Zolopa,et al.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.

[27]  F. Brun-Vézinet,et al.  Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received , 2003, Antiviral therapy.

[28]  Thomas D. Wu,et al.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors , 2003, AIDS.